Evolution of Hypodopaminergic Syndrome in Early Parkinson's Disease
Evolution of Hypodopaminergic Syndrome in Early Parkinson's Disease
The objective of this study is to describe the evolution of hypodopaminergic syndrome in
 patients with Parkinson's disease.
All patients to be included have been clinically described in the early phase of their
 disease, before instauration of dopaminergic treatment, in the context of a former study
 ("Non Motor Aspects in De Novo Parkinson's Disease (Honeymoon) NCT02786667") between june
 2012 and june 2016.

 3 to 5 years after this study, those patients who started dopaminergic treatment will be
 evaluated again.

 The objective of this study, which takes place 3 to 5 year after the initial evaluation, is
 to measure the evolution of apathy and other symptoms of the hypodopaminergic syndrome.

 Secondary objectives are the evolution of other parameters including pain, personality and
 behavior. All parameters measured have been determined of each patient in the Honeymoon
 study.
Inclusion Criteria:

 -  patients who participated in "Non Motors Aspects in De Novo Parkinson's Disease
 (Honeymoon)" NCT02786667

 -  Patients under dopaminergic treatment, with stable dopaminergic treatment for at least
 2 months

 -  Patients with medical insurance

 -  signed informed consent

 Exclusion Criteria:

 -  diagnosis other than Parkinson's Disease

 -  dementia (Mattis <130)

 -  patients protected by law (i.e. pregnant or parturient women)